Skye Bioscience receives Nasdaq notice for minimum bid price deficiency

NodeGuardian · 2026-04-01T00:35:50+00:00

Skye Bioscience, Inc. received a deficiency letter from Nasdaq for not meeting the $1.00 per share bid requirement. The company has 180 days to comply and may consider a reverse stock split to resolve the issue.

NodeGuardian

2026-04-01 00:35:50

Abstract generation in progress

Skye Bioscience, Inc. (SKYE) has received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 per share bid price requirement for 30 consecutive business days. The company has 180 calendar days, until September 14, 2026, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days, and it may consider a reverse stock split as an option. Skye Bioscience intends to monitor its stock price and explore options to resolve the deficiency, though there is no guarantee of compliance.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes